Sunday, 17 November 2013

Trial for Down's syndrome pregnancy test

A simple blood test during pregnancy which can detect Down's syndrome in the developing foetus is to be trialled by the NHS. The technique, known as Non-Invasive Prenatal Testing (NIPT), could significantly reduce the number of women needing invasive testing, which can cause miscarriage. The study, which is being carried out at Great Ormond Street Hospital, will assess how and when the blood test could be introduced across the NHS.

Currently a woman's risk is assessed using her age, an ultrasound scan, and markers in the blood. Those deemed at high risk of a child with Down's are then offered an invasive test. This involves using a needle to take a sample of either placental cells or of the fluid that bathes the baby - but this procedure carries a 1/100 chance of miscarriage. The aim of the new test is to reduce the number of women having the invasive test by more accurately assessing the risk.

The new blood test, which is already available privately, looks for tiny fragments of DNA from the placenta and the foetus floating in the mother's bloodstream. The test can analyse the free-floating DNA for extra copies of chromosome 21, which is the cause of Down's syndrome. It is thought to be 99% accurate, and those with a positive result will still have the option of undergoing the invasive procedure to confirm the result. Professor Lyn Chitty, from Great Ormond Street who is leading the trial, said; "It could very significantly reduce the number of invasive tests and increase detection, this is seriously exciting stuff and it would be great to get it into the NHS."

The NHS National Institute for Health Research funded trial will analyse the scale of the benefit, as well as the best way to inform mothers and train staff about the test. Professor Chitty explained that one of the very important aspects of the study is looking at ways to make sure women understand the test, so they will therefore know the implications of the results and be able to choose whether or not to have it. Dr Anna Mackie, from the UK National Screening Committee, said: "Early indications suggest that using NIPT to screen women who are found to be at a higher risk of having a baby with Down's syndrome would enable earlier and safer detection of the condition."

It is understood that the new test is approximately 99% accurate for women who have already been identified as being at high risk of having a baby with Down's syndrome. However, the researchers are interested to see whether that accuracy is maintained in women who have not been identified as high risk. The studies for this are still under way, but when they are completed the information obtained could then be provided to women and health professionals to improve understanding.

Jack

Wednesday, 30 October 2013

New understanding of how genes shape face

Scientists are starting to understand why one person's face can look so different from another's. Working on mice, researchers have identified thousands of small regions of DNA that influence the way facial features develop. The study also shows that tweaking genetic material can subtly alter face shape. The findings of the research, which were published in Science, could also help researchers to learn how facial birth defects arise. They said that even though the research was carried out in animals, the human face was likely to develop in the same way.

Professor Axel Visel, from the Joint Genome Institute at the Lawrence Berkeley National Laboratory in California, said: "We're trying to find out how these instructions for building the human face are embedded in human DNA."

The international team has found more than 4,000 "enhancers" in the mouse genome that appear to play a role in facial appearance. These short stretches of DNA act like switches, turning genes on and off. And for 200 of these, the researchers have identified how and where they work in developing mice. Prof Visel said: "In the mouse embryos we can see where exactly, as the face develops, this switch turns on the gene that it controls." The scientists also looked at what happened when three of these genetic switches were removed from mice: "This mice looked pretty normal, but it is really hard for humans to see differences in the face of mice," explained Prof Visel.

By comparing the transgenic mice with unmodified mice, the researchers found that the changes were very subtle. However some mice developed longer or shorter skulls, while others have wider or narrower faces. Prof Visel explained that what this tells us is that this particular gene also plays a role in development if the skull, and can affect what exactly the skull looks like. Understanding this could also help to reveal why and how things can go wrong as embryos develop in the womb, leading to facial birth defects. There are many types of craniofacial birth defects, with cleft lip and cleft palate being the two most common ones. They can affect feeding, speech, breathing, can require extensive surgery and have psychological implications.

Professor Visel added that scientists were just at the beginning of understanding the processes that shape the face, but their early results suggested it was an extremely complex process. He said it was unlikely in the near future that DNA could be used to predict someone's exact appearance, or that parents could alter genetic material to change the way a baby looks.

Jack

Saturday, 19 October 2013

Sleep cleans away brain toxins

Researchers have shown that the brain uses sleep to wash away the waste toxins that build up during a hard day's thinking. The team, from the US, believe that the "waste removal system" is one of the fundamental reasons for sleep. Their study, published in Science, showed that brain cells shrink during sleep to open up the gaps between neurons and allow fluid to wash the brain clean. They also suggest that the failure to clear away some toxic proteins may play a role in some brain disorders.

Another big question for sleep researchers is why do animals sleep at all when it leaves them vulnerable to predators? It has been shown to have a big role in the fixing of memories in the brain and learning, but a team at the University of Rochester Medical Centre believe that "housework" may be one of the primary reasons for sleep. Researcher Dr Maiken Nedergaard said: "The brain only has limited energy at its disposal and it appears that it must choose between two different functional states  - awake and aware or asleep and cleaning up."

Their findings build on last year's discovery of the brain's own network of plumbing pipes - known as the glymphatic system - which carry waste material out of the brain. Scientists, who imaged the brains of mice, showed that the glymphatic system became 10-times more active when the mice were asleep. Cells in the brain, probably the glial cells which keep nerves alive, shrink during sleep. This increases the size of the interstitial space, the gaps between brain tissue, allowing more fluid to be pumped in and wash the toxins away. Dr Nedargaard said this was a "vital" function for staying alive, but did not appear to be possible while the mind was awake. She commented: "This is purely speculation, but it looks like the brain is losing a lot of energy when pumping water across the brain and that is probably incompatible with processing information." She added that the true significance of the findings would be known only after human studies, but doing similar experiments in an MRI machine would be relatively easy.

Commenting on the research Dr Neil Stanley, an independent sleep expert, said: "This is a very interesting study that shows sleep is essential downtime to do some housekeeping to flush out neurotoxins." Many conditions, such as Alzheimer's or Parkinson's disease, which lead to the loss of brain cells are characterised by the build-up of damaged proteins in the brain. The researchers suggest that problems with the brain's cleaning mechanism may contribute to such diseases, but caution more research is needed. The charity Alzheimer's Research UK said more research would be needed to see whether damage to the brain's waste clearance system could lead to diseases like dementia, but the findings offered a "potential new avenue for investigation."

Jack

Tuesday, 15 October 2013

Alzheimer's breakthrough hailed as 'turning point'

The discovery of the first chemical to prevent the death of brain tissue in a neurodegenerative disease has been hailed as the "turning point" in the fight against Alzheimer's disease. A drug that could be taken by patients still needs a lot more work to develop, but scientists say a resulting medicine could treat Alzheimer's, Parkinson's, Huntington's and other diseases.

In tests on mice, the Medical Research Council showed all brain cell death from prion disease could be prevented. Prof Roger Morris, from King's College London, said: "This finding, I suspect, will be judged by history as a turning point in the search for medicines to control and prevent Alzheimer's disease." He went on to say that a cure for Alzheimer's was not imminent but: "I'm very excited, it's the first proof in any living animal that you can delay neurodegeneration. The world won't change tomorrow, but this is a landmark study."

The research team at the Medical Research Council Toxicology Unit, based at the University of Leicester, focused on the natural defence mechanisms built into brain cells. When a virus hijacks a brain cell it leads to a build-up of viral proteins. Cells respond by shutting down almost all protein production in order to halt the spread of the virus. However, many neurodegenerative diseases involve the production of faulty or "misfolded" proteins. These activate the same defences, but with more severe consequences. The misfolded proteins linger and the brain cells shut down protein production for so long that they eventually starve themselves to death. This process is repeated in neurons throughout the brain, and can destroy movement, memory, or even kill, depending on the disease. Safely disrupting this process could treat a wide range of diseases, because it is thought to take place in many forms of neurodegeneration. The researchers halted neurodegeneration by using a compound which prevented those defence mechanisms kicking in.

The study showed mice with prion disease developed severe memory and movement problems, and all of these mice then died within 12 weeks. However, the mice that were given the compound showed no signs of their brain tissue wasting away. Side effects are an issue though, as the compound also acted on the pancreas, meaning the mice developed a mild form of diabetes and lost weight. Any drug given to humans would need to act only on the brain, but this gives scientists and drug companies a starting point which they can then improve on.

Dr Eric Karran, the director of research at the charity Alzheimer's Research UK, said: "Targeting a mechanism relevant to a number of neurodegenerative diseases could yield a single drug with wide-reaching benefits, but this compound is still at an early stage. It will be important for these findings to be repeated and tested in models of other neurodegenerative diseases, including Alzheimer's disease."

Jack

Wednesday, 9 October 2013

Missing genes offer autism clues

A study suggests that the discovery of "missing" genes could help scientists understand how autism develops. US researchers looked at the genetic profiles of more than 431 people with an autism spectrum disorder (ASD) and 379 without. It was found that those with an ASD were more likely to have just one copy of certain genes, when they should have had two. UK experts said genetic factors were one promising area of research into the causes of autism.

About 1% of the population has an ASD. They can run in families - but scientists have not identified a cause. Gene additions or deletions happen in all of us, but it is which genes are affected that determines what the effect is.

Prof Joseph Buxbaum, who led the research team, said: "This is the first finding that small deletions impacting one or two genes appear to be common in autism, and that these deletions contribute to risk of development of this disorder." The researchers found many of the most common deletions in the autistic group were linked to autophagy - a kind of waste-disposal and renewal process for cells. Prof Buxbaum said: "There is good reason to believe that autophagy is really important for brain development because the brain produces many more synapses than it needs, and the excess needs to be pruned back." He explained that having too many or too few synapses both had the effect of not making communication work very well.

Carol Povey, director for the Centre for Autism at the UK's National Autistic Society said: "The causes of autism are still being investigated." Many experts believe that the pattern of behaviour from which autism is diagnosed may not result from a single cause. Therefore more research needs to be done before any concrete conclusions can be drawn about the causes and what this might mean for future developments.

Jack

Tuesday, 1 October 2013

Cancer drugs fund extended until 2016

The prime minister has announced that a £200m-a-year fund for life-enhancing cancer drugs is to continue until 2016. The Cancer Drugs Fund (CDF) was set up in 2011 to help patients in England access certain drugs before they get approval for widespread NHS use. The scheme was due to end next year, but David Cameron has pledged £400m to keep it running.

The move has been welcomed by cancer charities, but Labour accused the prime minister of "letting down" patients.

Sara Osborne, head of policy research at Cancer Research, praised the valuable role the fund would play in battling the disease and highlighted the tens of thousands of people who received treatment because of it. She said: "There's about 30 drugs that are available on the Cancer Drugs Fund, and over the last three years about 34,000 patients have had treatment that they would not have otherwise had, had the fund not existed."

The scheme was only set to continue until 2014 and campaigners raised concerns about where patients would turn for help when the funding ceased. David Cameron said the CDF had been a "massive success" and added that he would recommend its continuation beyond 2016 should he be re-elected. He commented: "People have lived longer and in some cases it has saved people's lives." Mr Cameron also said the government would be partnering with Cancer Research UK to carry out new research into the effectiveness of cancer drugs.

Another charity, Target Ovarian Cancer, said while the news was "positive", it warned it was "just a stop-gap". It highlighted the case of Jenny Bogle who failed to meet CDF criteria for Avastin, a drug shown to delay recurrence. Ms Bogle said: "I have a wealthy friend and an oncologist who are determined to keep me going for as long as possible so I was able to access Avastin privately in the end." She commented that: "It shouldn't be a matter of luck" and pointed out that, if she were living in a different postcode, were vulnerable or less pushy or didn't have the support, she probably would have died years ago.

Alongside the plans to extend the fund, David Cameron also announed that Genomics England - a government-owned organisation tasked with mapping the DNA of 100,000 patients with cancer and rare diseases - will begin a partnership with Cancer Research UK.

Jack

Saturday, 21 September 2013

Brain scan detects tau protein

Japanese scientists have developed a pioneering new brain imaging technique that can detect the build-up of destructive proteins linked to Alzheimer's disease. It could lead to new ways of diagnosing the condition and of testing the effectiveness of new drugs. The technology, reported in the journal Neuron, can identify inside a living brain clumps of a protein called tau that is closely linked to the disease. Alzheimer's Research UK said it was promising work.

Alzheimer's disease is a problem for researchers trying to come up with a cure. The brain starts to die years before any symptoms are detected, which means drugs are probably given too late. A diagnosis of Alzheimer's cannot be made with absolute certainty until a patient has died and their brain is examined. It is also not 100% clear what is the cause of the dementia and what are just symptoms. One protein, called tau, is very closely linked to the disease, with tangles of tau thought to be one way in which brain cells are killed.

The team, lead by the National Institute of Radiological Sciences in Chiba, used positron emission tomography to build a 3D picture of tau in the brain. The researchers developed a chemical that could bind to tau and then be detected during a brain scan.

Dr Magoto Higuchi, from the National Institute of Radiological Sciences in Japan, said: "Positron emission tomography images of tau accumulation... provide robust information on brain regions developing or at risk for tau-induced neuronal death." Dr Eric Karran, director of research at Alzheimer's Research UK, said: "This promising early study highlights a potential new method for detecting tau - a key player in both Alzheimer's and frontotemporal dementia - in the living brain." He also said that, with new drugs being developed to target tau, scans capable of visualising the protein inside the brain could be important for assessing whether treatments in clinical trials are hitting their target. If this method is proven to be effective, such a scan could also be a useful aid for providing people with an accurate diagnosis, as well as for monitoring disease progression.

Jack

Saturday, 14 September 2013

Adult tissue reversed to embryo state

Spanish researchers say that for the first time the living tissue inside an animal has been regressed back into an embryonic state. They believe it could lead to new ways of repairing the body, for example after a heart attack. However, the study showed that the technique led to tumours forming in mice.

The transformation has already been carried out in a laboratory, by treating skin samples with a mix of chemicals or genetic modification. Now scientists at the Spanish National Cancer Research Centre in Madrid have achieved the same results inside an animal. Lead researcher Prof Manuel Serrano said: "It is a surprising result, this was not expected, most of us thought that it would be impossible." The research group used genetically modified mice to switch on, when they were given a specific drug, production of four chemicals shown to reverse a tissue's destiny in the laboratory. Tissues were successfully transformed back into an embryonic state, but without further direction they rapidly developed into tumours.

Prof Robin Ali, from the Institute of Ophthalmology in London, is using stem cell technology to rebuild the retina to restore sight. He said the "ultimate goal" would be some treatment that could regenerate the back of the eye, but he also said that it was a long way off. He added: "This is a really elegant study with important implications for the field. It will be a monumental task to prove this is safe, as what you're doing is innately dangerous, but it is exciting as it's potentially a new strategy for regenerative medicine." The technique was able to turn back the clock further than any other stem cell technology, including stem cells taken from an embryo. Previous techniques produce stem cells that make the tissues found in the body; this study could also make those needed to support an embryo in the womb, such as the placenta.

Prof Robin Lovell-Badge, from the MRC's National Institute of Medical Research, said that he could not see this technique leading directly to therapies, but rather improving scientific understanding. He commented: "To me the interesting thing was the evidence that the cells correspond to an earlier stage of development." He also said that, if it can be repeated with human cells, it could have important research implications such as understanding the placenta and how to help maintain a pregnancy.

Jack

Friday, 6 September 2013

Ovarian cancer gene found in mice

Scientists in the UK have found a gene that, if faulty, may increase the risk of ovarian cancer. According to a new study, mice lacking the gene were twice as likely to develop ovarian tumours, as well as showing signs of infertility. Scientists at the London Research Institute, Cancer Research UK, say that if the gene has a similar role in humans it could lead to new screening tests. The gene that was being looked at in the study is known as Helq, and is involved in repairing damaged DNA.

It was discovered that mice lacking the gene were twice as likely to develop ovarian tumours compared with those with a normal copy. Dr Simon Boulton, senior author from Cancer Research UK's London Research Institute, said: "Our findings show that if there are problems with the Helq gene in mice it increases the chance of them developing ovarian and other tumours. This is an exciting find because this might also be true for women with errors in Helq, and the next step will be to see if this is the case." He went on to say: "If it plays a similar role in humans, this may open up the possibility that, in the future, women could be screened for errors in the Helq gene that might increase their risk of ovarian cancer."

Ovarian cancer is the fifth most common cancer in women in the UK; each year about 7,000 women are diagnosed with the disease and about 4,300 die from it. The lifetime risk of a woman developing ovarian cancer is about 2%, but this may be higher in women with a strong family history of ovarian cancer, breast cancer, or both.

Dr Julie Sharp, Cancer Research UK's senior science information manager, said the study pulled together clues from a series of experiments building a picture of cell faults that could lead to ovarian cancer in women. She said: "Ovarian cancer can be hard to diagnose early and treat successfully so the more we know about the causes of the disease, the better equipped we will be to detect and treat it."

Jack

Saturday, 31 August 2013

Blueberries cut risk of type-2 diabetes

According to a study in the British Medical Journal, eating more fruit - particularly blueberries, apples and grapes - is linked to a reduced risk of developing type-2 diabetes. Blueberries were found to cut the risk by 26% compared with 2% for three servings of any whole fruit - but fruit juice did not appear to have the same effect.

The research looked at the diets of a very large sample of over 187,000 people in the US; but Diabetes UK said the results of the study should be treated with caution.

Researchers from the UK, US and Singapore used data from three large studies of nurses and health professionals in the US to examine the link between fruit consumption and the risk of contracting type-2 diabetes. In these studies, 6.5% of participants (12,198 out of 187,382) developed type-2 diabetes. The studies used food frequency questionnaires to follow up the participants every four years, asking how often, on average, they ate a standard portion of each fruit. The types of fruit used in the study were grapes or raisins, peaches, plums or apricots, prunes, bananas, cantaloupe, apples or pears, oranges, grapefruit, strawberries and blueberries.

The researchers' analysis of the data showed that three servings per week of blueberries, grapes and raisins, and apples and pears significantly reduced the risk of type-2 diabetes. While all fruit was shown to reduce the risk, these types appeared to be particularly effective. The researchers said this could be due to the fact these fruits contain high levels of anthocyanins, which have been shown to enhance glucose uptake in mice.

When they looked at the effects of fruit juice consumption, the researchers found a slightly increased risk of type-2 diabetes. It was therefore calculated that replacing weekly fruit juice consumption with whole fruits could bring health benefits. For example, replacing fruit juice with blueberries could reduce the risk of contracting type-2 diabetes by 33%, with grapes and raisins by 19%, apples and pears by 13% - and with any combination of whole fruit by 7%. Replacing fruit juice with oranges, peaches, plums and apricots had a similar effect.

Qi Sun, study author and assistant professor at Harvard School of Public Health, said, in general, fruit juices contained less of the beneficial compounds found in whole fruits. He said: "The juicing process gets rid of the fruit, just leaving fluids which are absorbed more quickly, causing blood sugars and insulin levels to rise if they contain sugars." He went on to say: "To try to minimise the risk of type-2 diabetes as much as possible it is reasonable to reduce fruit juice consumption and increase consumption of whole fruits."

Dr Matthew Hobbs, head of research for Diabetes UK, said the study provided further evidence that eating plenty of whole fruit was a key part of the balanced diet that will minimise the risk of developing type-2 diabetes. However, he said the links between type-2 diabetes and specific types of fruit or fruit drinks should be treated with caution.

Jack

Saturday, 24 August 2013

New method for building body parts

Researchers in the UK have demonstrated a way of building body parts that is similar to the way a spider spins its web. The team at University College London used a constant stream of cells mixed with a polymer to weave new tissues. The team tested the technique by constructing blood vessels in mice, and think that the technique could produce better results than other ways of building body parts for transplant.

The team at UCL are using "electrospinning" technology to produce organs. They think it will overcome some of the challenges of seeding a scaffold by building the cells into the transplant in the first place. The process starts with a broth of cells and polymer; a 10,000 volt electric needle is then used to draw out a fibre.

Dr Suwan Jayasinghe said: "Like a spider weaves its web we are able to draw out this continuous fibre of polymer and cells and weave a web. We could make one as thick as a mattress and the cells will be embedded right through it." The electrospinning technology has been used to create blood cells by cross-stitching the fibres on to a rotating cylinder which is half submerged in a liquid to nourish the living cells. Dr Jayasinghe also said: "At the moment no technology can make an organ, we are coming up with the process to patch up a defective organ not replace an organ." The idea is that a patch of heart muscle could improve function after a heart attack.

However, it is early days for the field of electrospinning. In comparison, other methods for producing body parts are already being used in patients.

Jack

Saturday, 17 August 2013

A-level results

On Thursday I picked up my A-level results from my school and was happy to learn that I'd got exactly what I needed to get into my firm choice university. 

My grades were ABB in Maths, Chemistry and Human Biology respectively as well as a B in AS Critical Thinking. This meant that I had what I needed to get into the University of Nottingham to study Biochemistry and Genetics. 

Now that's over I'm looking forward to starting there and will spend the next few weeks getting everything ready and learning all the skills I'll need to survive in my self-catered accommodation. 

Jack

Bacteria in mouth may trigger bowel cancer

Researchers say they have uncovered how mouth bacteria may set off a chain reaction leading to bowel cancer. Two US studies have revealed that fusobacteria, which are commonly found in the mouth, cause overactive immune responses and turn on cancer growth genes. The microbes have already been linked to colorectal cancer but it was not known whether they were directly involved in tumour growth. Experts hope that, in addition to potential new treatments, the discovery could lead to better early diagnosis and prevention.

The first study, carried out by researchers at Harvard Medical School, showed that fusobacteria were present in high numbers in adenomas - a benign bowel growth that can become cancerous over time. The same researchers also did tests in mice showing that the bacteria speeded up the formation of colorectal tumours by attracting special immune cells, which then invade and set off an inflammatory response which can lead to cancer.

The second study, carried out by researchers at Case Western Reserve University, showed that fusobacteria had a molecule on their surface which enabled them to attach to and invade human colorectal cancer cells. The molecule - FadA - then switches on cancer growth genes and stimulates inflammatory responses to promote tumour formation. The synthetic compound which blocked FadA was found to completely halt the process, raising the possibility it could one day be used as a preventative treatment. The Case Western team also confirmed that FadA levels were much higher in tissues from patients with adenomas and colorectal cancer compared with healthy individuals.

Dr Wendy Garrett, the lead author of the Harvard study, said: "Fusobacteria may provide not only a new way to group or describe colon cancers but also, more importantly, a new perspective on how to target pathways to halt tumour growth and spread." She added that in future the presence of the bacteria in a tumour may be used to guide treatment decisions. Oliver Childs of Cancer Research UK said: "Our bodies contain many hundreds of microbes, many of which are beneficial and protect us against disease. But some can cause harm and this latest research gives compelling evidence that fusobacteria contribute to the development of certain bowel cancers by helping the cancer cells to grow." He went on to say: "If larger studies confirm this work, a potential next step will be to develop tests to spot people at higher risk of bowel cancer or drugs that eradicate the effects of the bacteria."

Jack

Saturday, 10 August 2013

Malaria vaccine shows promise in trials

According to researchers in the US, a malaria vaccine has shown promising results in early stage clinical trials. They found that, when given in high doses, the vaccine protected 12 out of 15 patients from the disease. The method used by the researchers was unusual because it involved injecting live but weakened malaria-causing parasites directly into patients to trigger immunity.

Lead author Dr Robert Seder, from the Vaccine Research Center at the National Institute of Health, in Maryland, said: "We were excited and thrilled by the result, but it is important that we repeat it, extend it and do it in larger numbers."

For several decades it has been known that exposure to mosquitoes treated with radiation can protect against malaria. However, studies have shown that it takes more than 1,000 bites from the insects over time to build up a high level of immunity, meaning it would be an impractical method for widespread protection. Instead, a US biotech company called Sanaria has taken lab-grown mosquitoes, irradiated them and then extracted the malaria causing parasite (Plasmodiom falciparum). These living but weakened parasites are then counted and placed in vials, where they can then be injected into a patient's bloodstream.

To carry out the Phase-1 clinical trial, the researchers looked at a group of 57 volunteers, none of whom had had malaria before. Of these, 40 received different doses of the vaccine, while 17 did not. They were then all exposed to the malaria-carrying mosquitoes. The researchers found that for the 17 participants not given the vaccine, and those given low doses, almost all became infected with malaria. However, for the small group given the highest dosage, only three of the 15 patients became infected after exposure to malaria.

Dr Robert Seder said: "Based on the history, we knew dose was important because you need 1,000 mosquito bites to get protection - this validates that. It allows us in future studies to increase the dose and alter the schedule of the vaccine to further optimise it. The next critical questions will be whether the vaccine is durable over a long period of time and can the vaccine protect against other strains of malaria." He added that the fact that the vaccine had to be injected into the bloodstream rather than into or under the skin made delivery more difficult.

In total there are currently about 20 malaria vaccine candidates in clinical trials. The most advanced is called RTS,S/AS01, which has been developed by the pharmaceutical company GlaxoSmithKline, and is in a Phase-3 clinical trial involving 15,000 children in Africa.

Jack

Saturday, 27 July 2013

Family cancer-history increases risk of multiple types

Research suggests that having cancer in the family can increase a person's chances of developing not only the same type of cancer, but others too. A study of 23,000 people in Italy and Switzerland concluded that for each of 13 cancer types, close relatives had an increased risk of the same disease. However there was also evidence that a family history of one cancer could significantly raise the risk of others.

The research, published in the journal Annals of Oncology, followed 12,000 patients with cancer at different sites in the body, who were compared with 11,000 people without cancer. The researchers collected information on family history of cancer, particularly in a first-degree relative (those who share about 50% of their genes such as a parent, sibling or child).

They discovered that people with a first-degree relative with cancer of the larynx had triple the normal risk of developing oral and pharyngeal cancer. Those closely related to someone with oral and pharyngeal cancer had a fourfold increased risk oesophageal cancer, while breast cancer doubled the risk of ovarian cancer for female family members. In addition to this men had a 3.4-fold increase in prostate cancer if a first-degree relative had bladder cancer. The research also confirmed some known cancer risks; they include a raised risk of women developing breast cancer if they have a family history of bowel cancer.

Study leader Dr Eva Negri, of the Mario Negri Institute for Pharmacological Research in Milan, Italy, said: "What this study has highlighted is that sometimes if you have a relative with one cancer your risk of another cancer can be increased. The relative risk of a different cancer generally tends to be lower than for the same cancer." She added that in some cases, the links between different cancers may be due to shared environmental factors, such as family smoking and drinking habits. However there was also evidence of genetic factors that affected multiple cancer sites in the body.

Jessica Harris, the senior health information manager at Cancer Research UK, explained that cancer risk is determined by a combination of genes we inherit from our parents, our lifestyles, and our environment. She said: "Whether or not someone in your family has had cancer, living a healthy life can really help to stack the odds in our favour, and reduce the risk of cancer. The main things you can do are to be a non-smoker, cut down on alcohol, and stay in shape by being active and eating a balanced diet."

Jack

Friday, 19 July 2013

Pioneering stem cell trial approved

The first trial of stem cells produced from a patient's own body has been approved by the Japanese government - Japan's health minister, Norihisa Tamura, ruled that the cells can now be tested in patients. Researchers in Japan will use the cells to attempt to treat a form of blindness - age-related macular degeneration. The announcement was described as a "major step forward" for research in this field.

There are already clinical trials taking place that use stem cells harvested from embryos, but this is ethically controversial and the cells will not match a patient's own tissues, so there is a risk of rejection. Induced pluripotent stem cells (IPSCs), however, are made by coaxing a sample of the patient's skin to become stem cells, so there should be no risk of rejection.

The trial will be run by the Riken Center for Developmental Biology and the Institute of Biomedical Research and Innovation Hospital in Kobe. Initially, six patients will receive transplants of cells to see if the procedure can restore their damaged vision.

Prof Chris Mason, an expert on regenerative medicine at University College London said: "This was expected, but it's obviously a major step forward. They [IPSCs] are beneficial for two main reasons. One, they are from the patients themselves so the chance of rejection is greatly reduced and there are the ethical considerations - they do not have the baggage which comes with embryonic stem cells." However the downside to IPSCs is that they were discovered much later than embryonic stem cells, so the science is not as advanced and therefore the technology is less safe.

Jack

Friday, 12 July 2013

Gene therapy trial 'cures children'

A disease that robs children of the ability to walk and talk has been cured by pioneering gene therapy to correct errors in their DNA, say doctors in a study published in Science. A second study published at the same time has shown a similar therapy reversing a severe genetic disease that affects the immune system. Gene therapy researchers described it as a "really exciting" development.

Babies born with metachromatic leukodystrophy appear healthy, but their development starts to reverse between the ages of one and two as part of their brain is destroyed. Wiskott-Aldrich syndrome leads to a defective immune system; it makes patients more susceptible to infections, cancers, and the immune system can also attack other parts of the body.

The treatment technique, developed by a team of researchers at the San Raffaele Scientific Institute in Milan, Italy, used a genetically modified virus to correct the damaging mutations in a patient's genes. Bone marrow stem cells are taken from the patient and then the virus is used to 'infect' the cells with tiny snippets of DNA which contain the correct coding instructions - these are then put back into the patient. The treatment was carried out on three children from families with a  history of metachromatic leukodystrophy, but before their brain function started to decline.

Dr Alessandra Biffi said: "The outcome has been very positive, they're all in very good condition, with a normal life and going to kindergarten at an age when their siblings were unable to talk." She said that all treatments had side effects and these patients needed to be followed for longer, but the evidence so far suggested the treatment was safe.

In the other study, which was published simultaneously in Science, symptoms such as repeat infections and eczema had lessened in the three patients treated. Prof Luigi Naldini, who leads the San Raffaele Telethon Institute for Gene Therapy, said: "Three years after the start of the clinical trial the results obtained from the first six patients are very encouraging. The therapy is not only safe, but also effective and able to change the clinical history of these severe diseases."

Jack

Friday, 5 July 2013

Stem-cell livers grown in lab

Tiny functioning human livers have been grown from stem cells in a laboratory by scientists in Japan. The scientists said they were "gobsmacked" when liver buds, the earliest stage of the organ's development, formed spontaneously. The team, reporting their findings in Nature, hope that transplanting thousands of liver buds could reverse liver failure.

Scientists around the world are trying to grow organs in the lab in order to overcome the shortage of organ donors. Some patients already have bladders made from their own cells, but dense solid organs such as the liver and kidneys are much harder to produce.

The team at the Yokohama City University were reproducing the earliest stages of liver development, similar to that in an embryo. They had mixed three types of cells - two types of stem cells and material taken from the umbilical cord. Unexpectedly, the cells began to organise themselves and appeared to curl up to form a liver bud. These buds were then transplanted into mice, where they hooked themselves up with the blood supply and began to function as little livers. This resulted in increased lifespans in the mice that had liver failure.

Prof Takanori Takebe said: "We just simply mixed three cell types and found that they unexpectedly self-organise to form a three-dimensional liver bud - this is a rudimentary liver. And finally we proved that liver bud transplantation could offer therapeutic potential against liver failure."

It is thought that other organs such as the pancreas, kidneys and even the lungs could be developed in the same way. However, turning this concept into a treatment is still a distant prospect. The buds are 4-5 mm in length but the researchers say they would need to develop buds that are much smaller and could be injected into the blood. The buds would not grow to be a whole new liver, but would embed themselves in the failing one and restore it.

Dr Varuna Aluvihare, a liver transplant physician at King's College Hospital in London, said:
"This is a great piece of work and as a proof of concept, very interesting. The real highlight is that such simple mixtures of cells can differentiate and organise themselves into highly complex issue structures that function well in an animal model." However he also said that the liver was very damaged in chronic liver disease so there were still questions about where the buds were transplanted and how they would function. The risk of a tumour developing after the transplant would also need to be assessed.

Jack

Saturday, 29 June 2013

UK government supports three-person IVF

The UK is expected to become the first country to allow the creation of babies using the DNA of three different people, after the government backed the new IVF technique. Draft regulations will be produced later this year and the procedure could be offered within two years. Experts say three-person IVF could eliminate debilitating and potentially fatal mitochondrial diseases that are passed on from mother to child, however opponents say it is unethical and could set the UK on a "slippery slope".

Mitochondria are the tiny organelles inside cells that produce energy for the body in the form of adenosine triphosphate (ATP); everyone inherits them from their mother as they are present in the egg cell which is fertilised by the sperm. Defective mitochondria affect one in every 6,500 babies, which can leave them starved of energy and results in muscle weakness, blindness, heart failure and death in the most extreme cases.

Thanks to the two new techniques that have been devised by scientists, it is now possible to take an empty donor egg with non-faulty mitochondrial DNA and then fertilise it with a gamete nucleus from each parent. This would allow a couple to have a child that is genetically related to them both, but does not carry the defective mitochondrial DNA. Because the mitochondria contain a small amount of DNA it also means that the child is created using the DNA from three people.

Earlier this year, a public consultation by the Human Fertilisation and Embryology Authority (HFEA) concluded that there was "general support" for the idea and that there was no evidence that the advanced form of IVF was unsafe. The chief medical officer for England, Prof Dame Sally Davies, said: "Scientists have developed ground-breaking new procedures which could stop these diseases being passed on, bringing hope to many families seeking to prevent their future children inheriting them." She said there were "clearly some sensitive issues here" but said she was "personally very comfortable" with altering mitochondria.

Jack

Saturday, 22 June 2013

Fall in excess diabetes deaths

Research suggests that the extra risk of dying for people with diabetes has fallen sharply since the mid 1990s. In 2009 people with diabetes were 1.5 times more likely than people without diabetes to die within a given time period - down from being two times as likely in 1996. The study that looked into this, in journal Diabetologia covering millions of Canadian and UK patients, concludes this may have resulted from better treatment and earlier diagnosis.

Since the mid 1990s the number of people diagnosed with diabetes in the UK has climbed from less than one and a half million to three million. The disease and its often fatal complications, which include heart disease, stroke and kidney failure, pose a huge and growing challenge for the NHS. However this study points to progress in cutting deaths.

The findings are based on population-based databases from Ontario and the UK over the years 1996 to 2009. The researchers compared mortality rates in people with diabetes, including types 1 and 2, and those without. In the UK cohort, covering more than three million patients, the excess risk of death for people with diabetes in 1996 was 114%; by 2009 this had fallen to 65%. In the Ontario database, comprising about 10 million patients, it fell from 90% to 51%. This narrowing of the mortality gap was seen across all age-groups and in both men and women. However, the authors acknowledge their findings should be treated with caution.

They speculate that the improvements may be due to more aggressive treatment, including control of blood pressure and blood glucose levels. But they say the findings may also reflect improved screening, meaning more patients nowadays have not had diabetes for so long. Dr Alasdair Rankin, director of research for diabetes UK, said the research was "really good news", but he warned there was still a long way to go. He said: "Every year many thousands of people with diabetes in the UK are still dying before their time. This is unacceptable and urgent action is needed to further improve the situation." There are also wide regional variations across the country in helping patients manage their condition so this should now become a key focus. By supporting patients to better manage their diabetes, progress can be made to reduce the number of patients who suffer complications including amputations or loss of sight.

Jack

Saturday, 15 June 2013

Patch offers alternative method for injections

A skin patch that can deliver vaccines cheaply and effectively has been shown off by its inventor, Prof Mark Kendall, at the TEDGlobal conference in Edinburgh. He said that using a patch rather than a needle could transform disease prevention around the world, and offered hope of usable vaccines for diseases such as malaria.

The nanopatch overcomes some of the drawbacks of syringe-given vaccines such as needle phobia and the possibility of contamination caused by dirty needles. Thousands of tiny projections in the patch release the vaccine which is applied into the skin in dry form. He explained: "The projections on the nanopatch work with the skin's immune system. We target these cells that reside just a hair's breadth from the surface of the skin." He went on to say: "It seems that we may have been missing the immune sweet spot which may be in the skin rather than the muscle which is where traditional needles go."

In tests at his laboratory in Queensland University, Brisbane, the nanopatch was used to administer the flu vaccine. Researchers noticed that the immune responses for vaccines administered with the nanopatch were completely different to those given by a traditional syringe. The amount of vaccine needed for it to be effective is also much lower, up to one hundredth of the traditional dose. As well as this, another shortcoming of traditional vaccines is that, because they are liquid, they need to be kept refrigerated between the lab and clinic. However this is not the case with the nanopatch which can be stored at 23°C for up to a year. This is significant because half of vaccines in Africa are not working because refrigeration has failed at some point in the chain.

The news of the nanopatch was given a huge welcome by the British Society for Immunology, Dr Diana Williamson commented: "This approach holds out hope for easy and large-scale vaccination, as it targets a type of immune cell, called the Langerhans cell, that is abundant in the skin. These cells avidly take up the vaccine and are able to kick-start the immune response." However she also warned that one of the potential issues with skin delivery is transit time and ensuring adequate delivery of the vaccine payload. In addition to this there may be issues of tolerability of the patch in some people. However, if these issues can be overcome, the approach does hold out the potential to dispense with conventional needle-based 'intra-muscular' delivery. The nanopatch will soon begin field tests in Papua New Guinea where vaccines are in short supply.

Jack

Saturday, 8 June 2013

MS 'immune training' trial

An experimental treatment to stop the body attacking its own nervous system in patients with multiple sclerosis appears safe in trials. The myelin sheath which coats the axons of nerves is destroyed in multiple sclerosis, by the immune system thinking that myelin is a foreign body. This leaves the nerves struggling to pass on messages. The study, which involved nine patients and was reported in Science Translational Medicine, tried to train the immune system to cease its assault on myelin.

The researchers, from Northwestern University Feinberg School of Medicine, took blood samples and coupled white blood cells to fragments of myelin. This was then injected back into patients to make them tolerate myelin. They reported that the therapy appeared safe, and despite the sample size being too small to prove whether it benefited patients, they did observe a calming of the immune reaction.

Prof Stephen Miller said: "Our approach leaves the function of the normal immune system intact. That's the holy grail." He continued to say: "We want to treat patients as early as possible in the disease before they have paralysis due to myelin damage, once the myelin is destroyed, it's hard to repair that."

Dr Susan Kohlhaas, head of biomedical research at the MS society, also commented: "Being able to specifically stop the immune system attacking myelin but still keeping it fully functional poses an exciting potential therapy for people with MS." She was intrigued by the success that had been shown in this small study, but said that more research is needed and she would eagerly await the results of any future larger clinical trials of this therapy.

Jack

Friday, 31 May 2013

Inner shell structure of HIV revealed

For the first time, researchers have unravelled the complex structure of the inner protein shell of HIV. The US team, reporting in Nature, also worked out exactly how all the components of the shell or 'capsid' fit together at the atomic level. Until now the exact structure had proved elusive because of the capsid's large size and irregular shape. However, now the structure has been identified, the finding opens the way for new types of drugs, according to the researchers from Pittsburgh.

It was already known that the capsid, which sits inside the outer membrane of the virus, was a cone-shaped shell made up of protein-units in a lattice formation. But because it is huge, asymmetrical and non-uniform, standard techniques for working out the structure have proved ineffective. The team used advanced imaging techniques and a supercomputer to calculate how the 1,300 proteins which make up the cone-shaped capsid fit together.

The process revealed critical interactions between molecules in areas that are necessary for the shell's assembly and stability. These potential vulnerabilities in the protective coat of the viral genome could be exploited by scientists designing new drugs to tackle the problem of HIV resistance, the researchers explained.

Study leader Dr Peijun Zhang, associate professor of structural biology at the University of Pittsburgh School of Medicine said: "The capsid is critically important for HIV replication, so knowing its structure in detail could lead us to new drugs that can treat or prevent the infection." Sh
e went on to say: "The capsid has to remain intact to protect the HIV genome and get it into the human cell, but once inside, it has to come apart to release its content so that the virus can replicate. Developing drugs that cause capsid dysfunction by preventing its assembly or disassembly might stop the virus from reproducing."

Prof Simon Lovell, a structural biologist at the University of Manchester, said not only had the researchers managed to achieve something that was very difficult, but had also found some really interesting results. He explained how HIV treatment is made problematic by the way it evolves so quickly, but this new knowledge could allow the creation of an entirely new class of drugs, to be used alongside the existing class in a multi-drug cocktail.

Jack

Saturday, 25 May 2013

Cancer cell enzymes aid immune system

Enzymes released by cancerous cells have a protective function and are not one of the "bad guys", according to researchers from the University of East Anglia. The study they conducted found that the MMP-8 enzyme sent a signal to the immune system to attack the tumour; and patients whose breast tumours have more of this enzyme seem to do better.

Scientists from UEA worked with clinicians at the Norfolk and Norwich University Hospital to look in detail at the patterns of MMPs in breast tumours from patients. Their study, published in the Journal of Biological Chemistry, reveals that the matrix metalloproteinase-8 enzyme (MMP-8) could be acting as the 'good guy' by alerting the immune system to the location of the tumour. It was previously thought that the production of MMPs by breast cancer cells helped to promote the growth of cancer. Drugs used to treat cancer in the 1990s, which blocked these enzymes, failed in the clinic, and this new research may explain why.

Prof Dylan Edwards, lead researcher from UEA's School of Biological Sciences, said that if breast cancer cells produce MMP-8 it causes them to produce two other inflammatory factors (IL-6 and IL-8) that have previously been shown to promote cancer. He said: "They were once thought to act like 'molecular scissors' to snip away at the scaffolding structures outside cells and clear a path for the cancer cells to invade and spread to other organs. However, breast tumour cells that over-produce MMP-8 don't survive long-term - the enzyme stops them growing." He went on to say: "We now think that in tumours, MMP-8 acts as a sort of 'find me' signal to the immune system, which then becomes activated to attack the tumour, which may help to explain its protective function."

It is still not known exactly how MMP-8 causes IL-6 and IL-8 to be activated, finding this out will be an important step forward which will help direct future research.

Dr Emma Smith, senior science information officer at Cancer Research UK, said: "This study provides very early clues as to how the MMP-8 protein may actually play the role of 'good cop' and recruit immune cells to fight breast cancer. And, rather than seeing the MMP-8 protein as a 'bad cop' in breast cancer, recent research has shown that levels of this protein are raised in women who do relatively well."

However these are early findings from cells grown in a lab, and more research will be required to see if the molecules found by the scientists alert immune cells to cancers in women.

Jack

Friday, 17 May 2013

Time-lapse embryo imaging improves IVF

According to \British research, time-lapse imaging which takes pictures of developing embryos can boost the success rate of IVF. The technique, reported in Reproductive BioMedicine Online, can be used to select embryos that have a low risk of defects.

Scientists at the CARE fertility group say such informed selection can improve birth rates by 56%. Other experts say the result is exciting, but the study of 69 couples is too small to be definitive. The research followed the couples at the CARE fertility clinic in Manchester last year, when 88 embryos were imaged and implanted.

The embryos were put into an incubator and imaged every 10-20 minutes. They were then classed as low, medium or high risk of chromosome abnormalities based on their development at certain key points. Eleven babies were born from the low risk group (61% success rate) compared to five from the medium risk group (19% success rate) and none from those which were deemed to be high risk.

Prof Simon Fishel, managing director of CARE fertility group, said: "In the 35 years I have been in this field this is probably the most exciting and significant development that can be of value to all patients seeking IVF." He went on to say: "This technology can tell us which embryo is the most viable and has the highest potential to deliver a live birth - it will have huge potential. This is almost like having the
embryo in the womb with a camera on them."

In standard IVF, embryos are removed from the incubator once a day to be checked under the microscope. This means they briefly leave their temperature-controlled environment and single daily snapshots of their development are possible. However, if the time-lapse method is used, the embryos don't leave the incubator until they are implanted allowing 5,000 images to be taken.

Dr Virginia Bolton, from the assisted conception unit at Guy's and St Thomas' NHS Foundation Trust, commented: "Removing embryos from the incubator potentially exposes them to damage, so it must be a good thing to be able to look at the pattern of development over time." She also said: "These results are very interesting but this is a very small study and any interpretation of the findings must be made with caution as we are dealing with the hopes and expectations of patients."

Despite having the potential to improve embryo selection and thus success in fertility treatment, this is only a small study and much more research will be required before this becomes a routine clinical tool.

Jack

Saturday, 11 May 2013

Mosquito parasite resistance

Researchers have discovered a strain of bacteria that can infect mosquitoes and make them resistant to the malaria parasite. The study, in the journal Science, showed the parasite struggled to survive in infected mosquitoes. The study took place at Michigan State University and looked at the Wolbachia bacterium, which commonly infects insects. Malaria is spread between people by the insects so it is hoped that giving mosquitoes malaria immunity could reduce human cases.

The bacterium passes only from females to their offspring, in some insects the bug is exceptionally good at manipulating insects to boost the number of females for its own ends. Wolbachia kills male embryos in some butterflies and ladybirds. In other situations, it can produce males that can only breed with infected females, and even allows some female wasps to give birth without mating.

Malaria-carrying Anopheles mosquitoes are not naturally affected by Wolbachia, but laboratory studies have shown that temporary infection made the insects immune to the malaria parasite. The challenge for the researchers was to turn a temporary infection into one that was passed on. They found a strain of Wolbachia that could persist in one species of mosquito, Anopheles stephensi, for the entire length of the study - 34 generations. Malaria parasites found it difficult to cope in these mosquitoes, with parasite levels fourfold lower than in uninfected bugs.

Research in Australia has shown that a different strain of Wolbachia can prevent the spread of dengue fever by mosquitoes. That research is more advanced and has been shown to work in large trials in the wild. Dr Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases in the US, said this study was a proof of concept that the same could be done for malaria.

Commenting on the study, Prof David Conway, of the London School of Hygiene and Tropical Medicine, said: "It is interesting and is the first report of Wolbachia clearly replicating, but a number of things took away the punch." He said the infected females produced fewer eggs than uninfected females, which meant the Wolbachia infection would struggle to spread in the real world. Also he cautioned that it was in just one species, Anopheles stephensi, which carries malaria in the Middle East and South Asia. Anopheles gambiae, in Africa, is a bigger problem. One of the researchers, Dr Zhiyong Xhi, said: "We have done only one strain. If we target Anopheles gambiae we would need to apply the same technique again." He added that if it could be shown to work then the 'Wolbachia tool' would need to be used in conjunction with currently available tools, such as mosquito nets and medication.

Jack

Friday, 3 May 2013

Scientists decode "molecular chatter" that causes spread of cancer cells

For the first time, US scientists have decoded the "molecular chatter" that makes cancer cells more aggressive and more likely to form tumours in other parts of the body. The discovery occurred as a result of bringing together specialists in cancer development with specialists in wound healing.

Principal investigator Prof Russell Taichman, from the University of Michigan, and colleagues, wrote about their discovery in the online issue of Nature Communications.

It is becoming increasingly clear that cancer cells are well-travelled adversaries that are capable of side-stepping the treatments we throw at them to try and stop their spread. For instance, a recent study that produced a catalogue of the physical properties of cancer cells, found they are nimbler and more aggressive than healthy cells because they are better able to pass through small spaces, and they exert a greater force on their environment. Now Taichman and colleagues have discovered a set of molecular signals that causes them to go into overdrive and spread.

For some time, scientists have known that tumours summon the body's healing cells, which is a major reason cancer is difficult to treat. A cancerous tumour acts like a wound that just won't heal: just like a benign tumour it sends out distress signals that recruit mesenchymal stem cells (MSCs) to heal it. These stem cells are then able to turn into several types of cell depending on the specific signals sent by the tumour. What Taichman and colleagues discovered is that when MSCs and cancer cells interact, the molecular messages that pass between them appear to send the cancer cells into overdrive and increase their ability to metastasise. He and his colleagues believe theirs is the first known study to explain molecular behaviour behind the series of changes that happen in the healing cells that result in cancer spread.

The interaction they decoded starts with a signal called CXCR6, which triggers the conversion of MSCs into fibroblasts, setting off a cascade that boosts metastasis:
"CXCR6 signalling stimulates the conversion of mesenchymal stem cells into cancer-associated fibroblasts, which secrete stromal-derived factor-1, also known as CXCL12. CXCL12 expressed by cancer-associated fibroblasts then binds to CXCR4 on tumour cells and induces an epithelial-to-mesenchymal transition, which ultimately promotes metastasis to secondary tumour sites."
This unique result was made possible because half of the researchers that worked on the study are experts in tumour development, and the other half are experts on wound healing. It came about because research associate Younghun Jung, who works in Taichman's lab and is first author of the paper, works in both fields. Taichman explains that it was her who put the two together and came up with the idea. Therefore this study is a good example of how surprising and useful discoveries in research can result from multidisciplinary work.

Jack

Saturday, 27 April 2013

Cutting cord early poses risk to babies

Experts say that cutting a baby's umbilical cord immediately after birth, which is currently standard practice, puts the child at risk or iron deficiency, which has been linked to brain development problems. Official guidelines are currently being examined - and professionals and campaigners say they should change. The reason for this is that leaving the cord attached for a few minutes would allow the blood within it to transfer to the baby, and raise the amount of iron within it's blood.

The existing guidance on cord-clamping was published in 2007, when the consensus was that cutting the cord immediately was the best option - something which had been the case for decades. Since then however, researchers have questioned whether that is still the case.

A paper from the Royal College of Obstetricians and Gynaecologists (RCOG) published in 2009, stated that babies whose umbilical cords are clamped immediately have lower iron stores for up to six months. Their suggestion is that the cord should not be cut until it has stopped pulsating naturally - anywhere between two and five minutes after birth; some hospitals have already changed their practice to meet this recommendation.

Commenting on the current re-evaluation of the guidance, an RCOG spokeswoman said: "The college recommends that the umbilical cord should not be clamped earlier than necessary and should always be based on clinical assessment of the situation." She went on to say: "Research has shown that delayed cord clamping of more than 30 seconds may benefit the newborn in reducing anaemia. It also allows time for the transfusion of placental blood to the newborn, especially in cases of premature birth." She did however add that there could be some cases where complications meant it was better to clamp the cord immediately.

Belinda Phipps, chief executive of the National Childbirth Trust (NCT) said: "When a baby is born about a third of the baby's blood is still in his/her cord and placenta. With no good evidence to support it, accepted practice is to accelerate the arrival of the placenta with an injection and clamp and cut the cord immediately, depriving the baby of this blood." She then said: "The NCT would like to see the default position become leaving the cord for a few minutes until it stops pulsating, unless the mother chooses to have an injection to speed the arrival of her placenta or unless the blood loss from the mother means her uterus must be encouraged, with drugs, to contract and expel the placenta quickly."

Prof Mark Baker, director of the centre for clinical practice at NICE, said all its guidelines were regularly updated to take into account developments in research. He also explained that all available evidence on the right time to clamp a newborn baby's cord is being considered, and their recommendation will represent what they believe is the best possible practice and will put mother and baby's safety first.

Jack

Friday, 19 April 2013

Explanation for cholesterol's damaging effect on the brain

A group of researchers, from the Linda Crnic Institute for Down's Syndrome and the Department of Neurology at the University of Colorado School of Medicine, have found that a single mechanism may underlie the damaging effect of cholesterol on the brain and blood vessels. High levels of blood cholesterol are known to increase the risk of both Alzheimer's disease and heart disease, but it has been unclear how cholesterol damages the brain to promote Alzheimer's disease.

Using insights gained from studying two much rarer disorders, Down's Syndrome and Niemann Pick-C disease, the researchers found that cholesterol wreaks havoc on the orderly process of cell division, leading to defective daughter cells throughout the body. In the study, published in the online journal PLOS ONE, Dr Antoneta Granic and Dr Huntington Potter show that cholesterol, particularly in the LDL form, causes cells in both humans and mice to divide incorrectly and distribute their already-duplicated chromosomes unequally to the next generation. The result of this is an accumulation of defective daughter cells with the wrong number of chromosomes and therefore the wrong number of genes. Instead of two copies of each chromosome, and thus two copies of each gene, some cells acquire three copies and some only one.

Granic and Potter's study of the effects of cholesterol on cell division included a prominent finding of cells carrying three copies of the chromosome (#21 in humans and #16 in mice) that encodes the amyloid peptide that is the key component of the neurotoxic amyloid filaments which accumulate in the brains of Alzheimer's patients.

Human trisomy 21 cells are significant because people with Down's syndrome have trisomy 21 in all of their cells from the moment of conception, and they all develop the brain pathology and many develop the dementia of Alzheimer's disease by the age of 50. Earlier studies by Granic, Potter and others have shown that up to 10% of cells in an Alzheimer's patient, including neurons in the brain, have three copies of chromosome 21 instead of the normal two. Because of this, Alzheimer's disease is in some ways a form of acquired Down's syndrome. Furthermore, mutant genes that cause Alzheimer's disease cause the same defect in chromosome segregation as is caused by cholesterol, thus indicating the presence of a common cell division problem in both familial and sporadic (non-familial) Alzheimer's disease. The new research also found trisomy 21 neurons in the brains of children with what, until now, was thought to be an unrelated neurodegenerative disease (Niemann Pick type C), caused by a mutation that affects cholesterol physiology. This result suggests that neurodegeneration itself might be linked to chromosome missegregation.

Identifying the specific problem caused by cholesterol will lead to completely new approaches to therapy for many human diseases, including Alzheimer's disease, atherosclerosis and possibly cancer, all of which show signs of defective cell division. Granic and Potter have already found a potentially simple approach to preventing cholesterol from causing cells to distribute their chromosomes unequally into their new daughter cells. Specifically, when cells in culture were treated with ethanol, the subsequent exposure to LDL cholesterol had no adverse effects on cell division, and each cell received the correct number of chromosomes.

Jack

Friday, 12 April 2013

Better oncogene understanding may lead to better cancer treatments

The Myc oncogene can disrupt the 24-hour internal rhythm in cancer cells, as several distinguished experts explained during their "Metabolic Pathway Regulation in Cancer" session at the 2013 American Association for Cancer Research meeting.

Timing of the body's molecular clock in normal cells synchronises the cellular need for energy with food intake during our sleep-wake cycle. Timing matters to the study of cancer in two ways; first, toxicity to some chemotherapy drugs is related to the time of day at which they are administered. For instance, a cancer drug called 5-fluorouracil is less toxic if given to a patient at night because the liver enzymes that detoxify it are more abundant at night. Second, several circadian rhythm genes have been implicated as tumour suppressors, although those exact connections are as yet unclear. Other researchers have also observed that many, but not all, cancer cell cultures lack proper circadian rhythm.

"Our hypothesis is that disrupting circadian rhythm benefits cancer cells by unleashing their metabolism from the constraints of the molecular clock," says Dr Brian Altman, one of the scientists involved. "In this regard, cancers don't sleep; they don't rest."

The study deals with the relationship of clock proteins in peripheral tissues associated with three types of cancer cells. The researchers surmise that Myc may affect circadian rhythm by promiscuously binding to promoter regions in key genes for maintaining circadian rhythm. In fact, using a well known genome browser they confirmed that Myc binds to circadian genes. The team also found that Myc upregulates another clock-regulated protein called NAMPT, potentially leading to dysregulated Sirt1 activity, another protein that is part of the complicated molecular clock. Inhibiting NAMPT downstream of Myc also led to changes in circadian gene expression, suggesting a role for the modulation of other proteins downstream of Myc in 'throwing a wrench in the clock's gears'.

Using cells from cultures of neuroblastoma, osteosarcoma, and hepatocellular carcinoma, which all overexpress Myc, they found that the abundance of Myc specifically upregulated the circadian protein Rev-erba. This protein in turn suppressed the oscillation of Bmal1 messenger RNA and decreased expression of the main clock protein Bmal1. What's more, the disrupted circadian oscillations in the Myc-expressing cancer cells could be partially rescued by inhibiting expression of Rev-erba.

"Our data suggests that Myc-driven cancers have altered circadian oscillation due to upregulation of Rev-erba and NAMPT, and that these Myc cancers may be good for chronotherapy," says Altman. "This work ties together the study of cell metabolism and cancer chronotherapy - If cells don't have to 'rest', they may replicate all the time, with no breaks at all." Another of the scientists involved, Annie Hsieh, said: "The understanding of these basic mechanisms from our work should lead to better cancer treatment strategies that reduce side effects and increase effectiveness."

Jack

Friday, 5 April 2013

Alzheimer's genetic markers identified

Genetic markers which could help highlight who is at risk from developing Alzheimer's disease have been identified by US scientists. The research identifies mutations that affect the build-up of tau proteins in the brain. UK experts said the study could help understand the changes that occur in the brains of Alzheimer's patients.

One of the new gene variants identified by the Washington University School of Medicine team was also shown to be linked to a small increased risk of developing Alzheimer's and a greater risk of cognitive decline.

Dr Alison Goate, who led the study, said: "We anticipate that knowledge about the role of these genes in Alzheimer's disease may lead to the identification of new targets from therapies or new animal or cellular models of the disease."

UK experts said the study adds to the number of genetic markers that have been linked to the development of Alzheimer's disease. Dr Doug Brown, director of research and development at the Alzheimer's Society, said: "In discovering new genes that have a link to Alzheimer's, this robust study helps scientists to better understand the way the brain changes when dementia develops. Research such as this may in the future help us to engineer treatments aimed at stopping such changes and therefore slowing or stopping the effects of dementia." He added: "These new gene markers, as important as they are, are likely to be a few of many that might affect a person's risk of developing Alzheimer's. However, it is important to stress that lifestyle factors also play a role, and research has shown that eating a balanced diet, exercising regularly, not smoking, and getting your blood pressure and cholesterol checked regularly are key ways to reduce your risk of dementia."

Jack

Saturday, 30 March 2013

DNA test reveals markers for inherited cancer risk

Over 80 genetic markers that can increase the risk of developing breast, prostate or ovarian cancer have been found in the largest study of its kind, which involved 200,000 people. The DNA of the test subjects, half of whom had cancer while the other half did not, was compared to reveal an individual's inherited risk of the diseases. British scientists, who led the research, believe it could lead to a DNA screening test within five years.

The research was led by scientists at the University of Cambridge, and the Institute of Cancer Research (ICR) in London and funded by Cancer Research UK (CRUK) and the Welcome Trust. The main findings of the research are published in five articles in the journal Nature Genetics.

Study author Professor Doug Easton said: "We're on the verge of being able to use our knowledge of these genetic variations to develop a test that could complement breast cancer screening and take us a step closer to having an effective prostate cancer screening programme."

The scientists were looking for common genetic variations - known as single nucleotide polymorphisms (Snps) - linked to the three cancers. Each alteration they found increased the patient's risk of cancer by a small amount, but a small minority of men with lots of the markers could see their risk of prostate cancer increase more than fourfold, and for women the breast cancer risk increased threefold.

The test could also help the one in 300 women who carry a faulty gene known as BRCA1 or BRCA2. Two thirds of them will develop breast cancer before the age of 80 and 45% who carry BRCA1 will get ovarian cancer. By combining the gene test for BRCA1 and BRCA2 with this extra genetic information, women who have a high number of the newly identified markers could find they have nearly a 100% risk of getting breast cancer. In contrast, those with the protective versions of the genetic changes could see their risk drop to as little as 20%.

Dr Antonis Antoniou, CRUK senior fellow at the University of Cambridge, said: "Our research puts us on the verge of being able to give women a much more accurate picture of how likely they are to develop breast or ovarian cancer and would help to guide them about the most appropriate type and time of prevention or monitoring options for them."

The research also sheds light on the risk of prostate cancer in men, which unlike breast cancer does not currently have a screening programme. The average lifetime risk of a man developing prostate cancer is one in eight, but for the 1% who carry a significant number of genetic alterations, the risk rises to one in two. Sixteen of the 23 newly identified genetic markers are associated with aggressive forms of the disease so may help clinicians and patients decide on the best form of treatment. Prof Ros Eles, from the ICR, said: "These results are the single biggest leap forward in finding the genetic causes of prostate cancer." He went on to say: "If further studies show such men benefit from regular screening, we could have a big impact on the number of people dying from the disease, which is still far too high."

Jack

Saturday, 23 March 2013

Scientists identify gene fault with "domino effect" on cancer risk

Scientists have identified a brand new genetic mechanism that raises the risk of cancer via a domino effect on DNA - with one gene fault triggering a second, cancer-causing mutation. The team, from The Institute of Cancer Research, London, found that some cancer patients inherit a weak point in their DNA which appears to leave one of their chromosomes vulnerable to snapping and becoming mutated.

The researchers hailed the finding, which was published in Nature Genetics, as a "very important discovery" that opens up new avenues for cancer treatment and prevention. The study sheds new light on the causes of multiple myeloma, a type of blood cancer, which affects around 4,700 patients in the UK each year - and could have implications for other types of cancer. It is the first time scientists have found evidence that inheritance of a gene fault can increase the risk of suffering a specific chromosomal mutation - in this case one that can drive development of cancer.

In the study, which was funded by a number of organisations, the DNA of 1,655 patients with myeloma was assessed and compared with people in the general population. This was to explore whether the patients had inherited genetic faults which had increased their risk of developing the disease. They then found that inheritance of a specific DNA range termed CCND1 G870A was associated with an 80% increase in the risk of developing a sub-type of myeloma affecting about a fifth of patients. This sub-type is known to be triggered by a specific chromosomal translocation (a type of DNA breakage and rearrangement) designated by the code t(11;14). The translocation forms a mutant piece of DNA that drives cancer by activating several genes.

Study author Professor Richard Houlston, Professor of Molecular and Population Genetics at the Institute of Cancer Research, said: "It's the first time anyone has identified a specific gene fault that raises the risk of developing a second specific type of DNA damage. Not only is the discovery valuable for our understanding of multiple myeloma, but it also demonstrates the value of studying specific genetic sub-types of cancer, rather than grouping them all together as one disease." Co-author Professor Gareth Morgan, Head of Molecular Haematology at the Institute of Cancer Research and Head of the Myeloma Unit at The Royal Marsden, also commented: "This is a very important discovery, which opens out our understanding of cancer genetics and gives us new avenues for treatment and prevention." He continued to say: "Now that we have found a genetic risk factor for a particular sub-type of multiple myeloma, I'm hopeful we can design more targeted treatments for the people who develop it. In cancer research we tend to group different sub-types together, but this research proves that we need to move away from this approach and investigate sub-types at a molecular level."

Jack

Saturday, 16 March 2013

Early HIV drugs could functionally cure around 10%

According to researchers in France, rapid treatment after HIV infection may be enough to "functionally cure" about a 10th of those diagnosed early. They reached this conclusion after having analysed 14 people who stopped therapy, but have since shown no signs of the virus resurging.

The group of 14 patients, known as the Visconti cohort, all started treatment within 10 weeks of being infected. These patients were able to be diagnosed early as they turned up in hospital with other conditions and HIV was found in their blood. The patients each stuck to a course of antiretroviral drugs for 3 years on average, but then stopped taking them; the drugs are only able to keep the virus in check and unable to completely eradicate it from its hiding places within the immune system. Therefore, when treatment stops, the virus is expected to bounce back, but in the case of the Visconti patients this did not happen.

Dr Asier Saez-Cirion, from the institute Pasteur in Paris, said: "Most individuals who follow the same treatment will not control the infection, but there are a few of them who will." He said that 5-15% of patients may be functionally cured by attacking the virus soon after infection, meaning they would no longer require drugs. This patients would still have HIV, as the virus is not completely eradicated, but it is a kind of remission of the infection.

The researchers' latest study, which can be found in the journal PLoS Pathogens, analysed what happened to the immune system of the patients. It is now understood that early treatment may limit the number of unassailable HIV hideouts that are formed, but it is "unclear" why only some patients were functionally cured. Dr Andrew Freedman, a reader in infectious diseases at Cardiff University School of Medicine, said the findings were "certainly interesting". He went on to say: "The presumption is that they've started treatment very early and the virus hasn't spread to so many of the long-term reservoirs and that's why it works. Whether they'll control it forever, or whether it'll be for a number of years and subsequently they will progress and the virus will reappear, we don't know." Deborah Jack, the chief executive of the National AIDS Trust said it was "exciting times" in progress towards a HIV cure, but the key was early treatment.

Jack

Friday, 8 March 2013

Baby 'cured' of HIV by early drug treatment

A baby girl in the US, who was born with HIV, appears to have been cured by very early treatment with standard drug therapy. The child is now two-and-a-half years old and has been off medication for about a year with no signs of infection.

If the girl stays healthy it would be the world's second reported 'cure', after Timothy Ray Brown who was the first person to recover from HIV in 2007. His infection was eradicated using an elaborate treatment for leukaemia that involved the destruction of his immune system, followed by a stem cell transplant from a donor with a rare genetic mutation that resists HIV infection. In contrast to this, the case of the US baby involved a cocktail of widely available drugs, known as antiretroviral therapy, already used to treat HIV infection in infants. This suggests that the swift treatment wiped out HIV before it could form hideouts in the body.

The baby was born in a rural hospital but was then transferred to the University of Mississippi Medical Center in Jackson. Once there, paediatric specialist Dr Hannah Gay put the infant on a cocktail of three standard HIV-fighting drugs at just 30 hours old, even before laboratory tests came back confirming the infection. The treatment continued for 18 months, at which point the child disappeared into the medical system. Five months later the mother and child turned up again but had stopped the treatment in this interim; the doctors then carried out tests to see if the virus had returned and were astonished to discover that it had not.

Dr Rowena Johnston, of the foundation for Aids Research, said it appeared that the early intervention by Dr Hannah Gay had worked, and praised the work as "very exciting". She also described how many doctors in six different laboratories had all applied different, very sophisticated tests trying to find HIV in the infant and none were able to find any. This led her to say: "We really can quite confidently conclude at this point that the child does very much appear to be cured." A spokeswoman for the HIV/Aids charity the Terrence Higgins Trust also commented: "This is interesting, but the patient will need careful ongoing follow-up for us to understand the long-term implications for her and any potential for other babies born with HIV."

Jack

Saturday, 2 March 2013

Cancers "shuffle their genetic pack" in order to resist treatment

It is already known that because of "chromosomal instability" cancer cells are able to "reshuffle" their chromosomes, thus increasing cell diversity in tumours. New research now reveals that if bowel cancer cells lack one of three genes they are able to carry out the genetic reshuffling very quickly. The researchers, led by Charles Swanton, a professor based at Cancer Research UK's London Research Institute and the UCL Cancer Institute, write about their findings in the online version of Nature.

Recent work carried out by Cancer Research UK and other groups shows that a tumour has a complex genetic landscape, and is beginning to change the way scientists understand the disease. One explanation for why this happens is that it increases the genetic diversity of the cancer cells, allowing them to adapt to new environments, spur tumour growth, or help resist treatment.

Swanton says that by uncovering how cancer cells manage to continually shuffle their genetic pack, it may be possible to turn their strength into a weakness, and create so much instability that the cells can't function normally and die. He went on to say: "We're now looking for ways in which this process can be targeted in order to tip cancer cells over the edge."

Normal cells have 46 chromosomes, but each time cancer cells divide they gain or lose whole or large fractions of chromosomes; this results in an imbalance in the number of chromosomes per cell (a state known as "aneuploidy"). Because of this, chromosomal instability is a defining characteristic of most human cancers. It also means that a tumour can contain cells of enormous genetic diversity, making them increasingly difficult to treat.

What Swanton and his colleagues found was that loss of any of three particular genes on a chromosome region known as 18q, interfered with the normal copying process, which led to mistakes in chromosome separation. By adding nucleotides to bowel cancer cells lacking all three of the genes, Swanton and colleagues found they could dramatically reduce chromosomal instability, and prevent further copying errors and the genetic shuffling.

Nic Jones, professor and chief scientist at Cancer Research UK, says it is not just in bowel cancer that 18q is missing, which perhaps suggests that this process is common to other types of cancer. He also said: "By understanding how cancer cheats at life's card-game, we can see how an individual person's cancer can be so complex and varied" and "Scientists can now start looking for ways to prevent this happening in the first place or turning this instability against cancers."

Jack

Saturday, 16 February 2013

Improved understanding of cancer cell surface protein

Researchers from the University of California and the Lawrence Berkeley National Laboratory have provided important new details about the activation of the epidermal growth factor receptor (EGFR). The receptor is a cell surface protein that has been strongly linked to a large number of cancers and is a major target for cancer therapies.

Jay Groves, one of the leaders of the research, says: "The more we understand about EGFR and the complex molecular machinery involved in the growth and proliferation of cells, the closer we will be to developing new and more effective ways to cure and treat the many different forms of cancer." Groves, who holds positions at both Berkeley Lab's Physical Biosciences Division and UC Berkeley's Chemistry Department, as well as the Howard Hughes Medical Institute, is one of two corresponding authors of a paper in the Journal Cell that describes the research. The other author is John Kuriyan, who also holds positions at Berkeley Lab, UC Berkeley and HHMI.

Once a protein that is coded for by genes has been assembled from amino acids, it may also need to be activated by post-translational processes, such as autophosphorylation in which phosphate is added. Protein activation can affect many important cellular processes including proliferation, differentiation and migration. Cancer is basically a case of these cellular functions gone wild, which often results from problems with the EGFR. However, despite its well-known links to cancer, EGFR activation is only partially understood.

As one of a group of receptors known as receptor tyrosine kinases, EGFR features a ligand-binding domain on its extracellular side and a kinase domain on its intracellular side. The explanation for EGFR activation is that the binding of the ligand, EGF, to its extracellular side induces dimerization of the receptor, the process in which two identical molecules combine to form a single compound molecule. This in turn brings together the kinase domains on the intracellular sides of the dimer, allowing them to phosphorylate one another. Groves believes that while this picture is accurate, it is an oversimplification of the mechanics behind the process because isolated intracellular kinase domains in solution can be active on their own at relatively low concentration, without EGF ligand-induced dimerization.

By measuring autophosphorylation as a function of EGFR, Groves, Kuriyan and their colleagues discovered that structural coupling between the EGFR transmembrane helix and extracellular juxtamembrane modules in addition to EGF ligand-engagement is required for EGFR activation. This structural coupling allows dimerization to take place in the presence of the EGF ligand.

With the mechanics behind EGFR activation now fully explained, Groves and his colleagues are now applying their techniques to another group of receptor tyrosine kinases, the Eph receptors, as well as T cell receptors that are so important to the immune system.

Jack